
==== Front
Drugs Real World Outcomes
Drugs Real World Outcomes
Drugs - Real World Outcomes
2199-1154
2198-9788
Springer International Publishing Cham

38954190
430
10.1007/s40801-024-00430-5
Original Research Article
PCSK9 Inhibitors and Infection-Related Adverse Events: A Pharmacovigilance Study Using the World Health Organization VigiBase
https://orcid.org/0009-0006-1328-2299
Park Dahyun 1
https://orcid.org/0000-0003-2622-6553
Bea Sungho 2
https://orcid.org/0000-0001-9621-5302
Bae Ji-Hwan 2
https://orcid.org/0000-0001-6556-9984
Lee Hyesung 12
https://orcid.org/0000-0003-2733-0715
Choe Young June 3
https://orcid.org/0000-0003-1010-7525
Shin Ju-Young shin.jy@skku.edu

124
http://orcid.org/0000-0003-4244-6126
Kim Hoon wisekh@skku.edu

12
1 https://ror.org/04q78tk20 grid.264381.a 0000 0001 2181 989X Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea
2 https://ror.org/04q78tk20 grid.264381.a 0000 0001 2181 989X School of Pharmacy, Sungkyunkwan University, 2066, Seobu-ro, Jangan-gu, Suwon, Gyeonggi-do South Korea
3 grid.411134.2 0000 0004 0474 0479 Department of Paediatrics, Korea University Anam Hospital, Seoul, South Korea
4 https://ror.org/04q78tk20 grid.264381.a 0000 0001 2181 989X Department of Clinical Research Design and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, South Korea
2 7 2024
2 7 2024
9 2024
11 3 465475
1 5 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Aims

Protein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are novel lipid-lowering agents used in patients with cardiovascular disease. Despite reassuring safety data from pivotal trials, increasing evidence from real-world studies suggests that PCSK9i increase the risk of bacterial and viral infections. Therefore, this study aimed to identify signals of infection-related adverse events (AEs) associated with PCSK9i.

Methods

We performed an observational pharmacovigilance study using the World Health Organization’s VigiBase, recorded up to December 2022. We included individual case safety reports (ICSRs) of PCSK9 inhibitors, alirocumab and evolocumab, and compared them with those of other drugs. Infection-related ICSRs were retrieved from the Medical Dictionary for Regulatory Activities System Organ Class ‘infections and infestations.’

Results

Among 114,293 reports (258,099 drug–AE pairs) related to PCSK9 inhibitors, 54% included female patients, 41% included patients aged ≥65 years, and 82% included patients who received evolocumab. Additionally, beyond AEs recognized by regulatory authorities, organ infections such as influenza (reporting odds ratio [ROR] 2.89, 95% confidence interval [CI] 2.74–3.05), gastric infections (ROR 2.47, 95% CI 1.63–3.75), and kidney infections (ROR 1.36, 95% CI 1.06–1.73) were observed. Sensitivity analysis indicated a heightened risk of infection-related AEs associated with PCSK9i regardless of the specific drug type.

Conclusions

In addition to the labelled respiratory infections, six infection-related symptoms in the gastrointestinal, urinary, and renal organs were identified. Our findings support the need for systematic surveillance of infections among PCSK9i users.

Supplementary Information

The online version contains supplementary material available at 10.1007/s40801-024-00430-5.

http://dx.doi.org/10.13039/501100003569 Ministry of Food and Drug Safety 21153MFDS607 22183MFDS433 Shin Ju-Young http://dx.doi.org/10.13039/501100014188 Ministry of Science and ICT, South Korea NRF-2022M3C1A3092022 Kim Hoon issue-copyright-statement© Springer Nature Switzerland AG 2024
==== Body
pmcKey Points

This retrospective observational study investigated the association between protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and infection-related adverse events using the World Health Organization’s (WHO) VigiBase. In the patient cohort receiving PCSK9 inhibitors, 82% were reported to have been administered evolocumab.	
In addition to the potential respiratory infections listed on the label, a broad range of infection safety profiles associated with PCSK9 inhibitors, including gastrointestinal, renal, skin, and respiratory infections, were identified. The most significant adverse drug reactions occurred within approximately 5 months of treatment.	
Given that most patients prescribed PCSK9 inhibitors are older adults, monitoring for infectious disorders should be performed during the early stages of treatment in this vulnerable population.	

Introduction

Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide [1–4]. According to the recent guidelines of high-profile cardiovascular societies, maintaining optimal low-density lipoprotein cholesterol (LDL-C) levels can help prevent the occurrence of CVD [5–9]. Previous studies have demonstrated the efficacy of lipid-lowering therapy (LLT) in reducing the risk of future cardiovascular events [10–15]. Recently, the newest class of LLT, i.e., protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, demonstrated a remarkable reduction in LDL-C levels among patients treated with statins that are tolerant to treatment [16, 17]. This is consistent with trials where PCSK9 inhibitors were associated with a significant reduction in LDL‐C levels (up to 62%) and a 48% decrease in cardiovascular outcomes [18–21].

Despite these clinical benefits, the association between PCSK9 inhibitors and infectious complications remains controversial. In the ODYSSEY trial, the PCSK9 inhibitor-treated group showed a higher risk of infection-related adverse events (AEs) than that of the placebo group, including respiratory tract diseases such as influenza and nasopharyngitis [22–26]. In the FOURIER trial, patients treated with evolocumab exhibited a higher risk of nasopharyngitis than those in the placebo group (7.8% vs 7.4%) [27]. Several biological mechanisms indicate that PCSK9 inhibitors may cause bacterial infection through the excessive reduction of plasma cholesterol [28]. Moreover, PCSK9 inhibitors likely induce viral entry by enhancing the expression of LDL receptor (LDL-R) and CD81 levels to facilitate viral propagation [29]. Although it is biologically plausible that PCSK9 inhibitors may be linked to infections, it is imperative to assess the association between PCSK9 inhibitors and infection. A recent systematic review and meta-analysis study demonstrated that there is no detrimental association between PCSK9 inhibitors and the risk of severe infection, including sepsis [30]. However, no studies have explored the relationship between PCSK9 inhibitors and comprehensive infection-related AEs utilizing global databases, and epidemiological evidence is still lacking [31, 32].

With the increasing application of PCSK9 inhibitors in clinical settings, particularly for older adults, it is important to elucidate their infection-related safety profiles. Therefore, we performed an observational pharmacovigilance study to investigate the association between PCSK9 inhibitors and infection-related AEs using the World Health Organization’s (WHO) VigiBase.

Methods

Data Source

VigiBase is a global database maintained by the WHO that records all potential AEs associated with medicinal products. It is the largest unique database worldwide, with more than 30 million individual case safety reports (ICSRs) on suspected drug side effects from more than 130 countries since January 1967. The database contains information on patient demographic characteristics (age, sex, and region), drug usage (suspected and concomitant drugs), and reported effects (date of occurrence and seriousness) from both regulatory and voluntary sources. It is composed of spontaneous reports from multiple groups, including healthcare professionals, patients, and pharmaceutical companies in the post-marketing setting. The seriousness of the safety reports in VigiBase is classified by reporters according to the seriousness criteria of the WHO–Uppsala Monitoring Centre (WHO-UMC). The ICSR database in VigiBase is linked to medical classifications such as the Medical Dictionary for Regulatory Activities (MedDRA) for AEs. These VigiBase classifications enable structured data entry, retrieval, and analysis with different levels of precision. The ICSR reports in VigiBase are primarily sourced from the VigiFlow database, which aggregates data from various stakeholders such as healthcare professionals, the pharmaceutical industry, and patients across WHO member states. VigiFlow serves as the national repository for ICSRs and is then utilized in the generation process of the VigiBase database. Unlike VigiFlow and VigiLyze, which are part of the WHO's Pharmacovigilance tools, VigiBase is a raw database that focuses more on clinical information and adverse event data [33]. We used adverse drug reactions (ADRs) coded using MedDRA terms (version 24.1 at the time of the search).

Study Design

We conducted an observational, retrospective pharmacovigilance study of patients worldwide who were administered PCSK9 inhibitors, including alirocumab and evolocumab, using VigiBase. We utilized all available Vigibase sources from 1968 to 2022 for pharmacovigilance studies, given that the signals are detected based on existing information. To identify safety reports related to PCSK9 inhibitors, we excluded all ICSRs medication information missing and suspected duplicates. Additionally, reports identified as suspected or interacting drugs were excluded, along with safety reports without records of potential AEs in VigiBase (Fig. 1). The study drug was defined by obtaining a unique drug-chemical code for the drug of interest using the terms ‘alirocumab,’ ‘Praluent,’ ‘evolocumab,’ and ‘Repatha.’ Administrative information (reporter type and country), demographic data (age and sex), drug use (time to infectious AE onset, drug indication, and seriousness of infectious AE), and AE datasets (infection-related and co-reported AEs with infectious ADRs in each safety report) were collected.Fig. 1 Flowchart for selection of reports on PCSK9 inhibitors. PCSK9 protein convertase subtilisin/kexin type 9, WHO World Health Organization

Outcome

This study included all infection-related AEs classified by group queries according to the MedDRA. All ICSRs that reported alirocumab or evolocumab as a suspected drug and at least one infectious ADR, as defined by the preferred terms (PTs), were retrieved. Given the PTs for various infection-related AEs, we categorized the infectious diseases based on the underlying primary system organ class (SOC) ‘infections and infestations’ using the MedDRA classification (version 24.1). To distinguish between the organs affected by infection-related diseases, we used secondary SOC (Supplementary Table 1, see electronic supplementary material [ESM]).

Statistical Analysis

Descriptive analyses were conducted for patients receiving PCSK9 inhibitors, and the proportions were calculated using categorical variables. Disproportional statistical analysis was used to evaluate drug AEs in the pharmacovigilance studies.

The association of infection-related AEs with PCSK9 inhibitors compared with other drugs was assessed using a disproportionality method specific to case–non-case studies. The disproportionality signal indicates a valid connection between PCSK9 inhibitors and specific side effects if the proportion of AEs of interest is significantly higher for the drug of interest than for any other drug [34].

We used the reporting odds ratio (ROR) and information component (IC) to report the findings of the disproportional analysis. The ROR is a frequentist measure of association derived from the contingency table of the drug and the number of AEs. The higher the ROR, the more statistically relevant the pharmacovigilance AE signal. Because the ROR estimate has been demonstrated to be the most definitive in at least three cases of AEs of interest [35], we limited the number of reported AEs to at least three. Thus, the ROR and 95% confidence interval (CI) were used in this study, and a lower bound of 95% CI ≥1 was considered a signal. IC is a Bayesian neural network-based disproportionality method that is calculated using the observed and expected numbers of reports for a drug–ADR combination. A positive IC value (≥0) indicates a higher number of reports than expected.

In addition to the infection-related AEs associated with PCSK9 inhibitors, we identified co-reported AEs. In this study, we performed a descriptive analysis of AEs other than infection-related AEs within the same report. The frequencies of the top 10 SOCs co-reported with infection-related AEs are demonstrated [36].

Time-to-onset (TTO) is the time interval between the date of PCSK9 inhibitor administration and the start of the reaction. The time to infection-related AE onset was determined by eliminating the TTO values <0 or the number of infection-related AEs <5.

Finally, to assess whether the higher risk of infection-related AEs can be attributed to the comparator, we conducted a sensitivity analysis by substituting the comparator with statins (atorvastatin, simvastatin, pravastatin, rosuvastatin, and fluvastatin). All statistical analyses and VigiBase data management were performed using the SAS package (SAS Institute, Cary, NC, USA), version 9.4.

Results

Characteristics of Adverse Events (AEs)

Among the 31,923,227 ICSRs, 114,293 were likely associated with PCSK9 inhibitors, including 20,603 (18% of associated PCSK9 inhibitors) reports on alirocumab and 93,690 (82% of associated PCSK9 inhibitors) reports on evolocumab. Among patients receiving PCSK9 inhibitors, 41.3% were ≥65 years old and 53.7% were women. Most ICSRs for the study drugs reported in VigiBase were from the United States (87.3%). The number of reports on the usage of PCSK9 inhibitors increased between 2019 and 2020 (40.1%). Healthcare professionals reported 70,180 cases (61.4%). The number of safety reports for these two drugs increased continuously between 2015 and 2022 (Table 1).Table 1 Baseline demographic characteristics of the study population

Characteristics, n (%)	PCSK9 inhibitors	
Overall
(n = 114,293)	Alirocumab
(n = 20,603)	Evolocumab
(n = 93,690)	
Age group, y	
 0–17	93 (0.1)	5 (0.0)	88 (0.1)	
 18–44	2045 (1.8)	409 (2.0)	1636 (1.8)	
 45–64	29777 (26.1)	4950 (24.0)	24827 (26.5)	
 Above 65	47229 (41.3)	8115 (39.4)	39114 (41.8)	
Sex	
 Male	46148 (40.4)	7610 (37.0)	38538 (41.1)	
 Female	61341 (53.7)	10326 (50.1)	51015 (54.5)	
Region	
 Africa	3 (0.0)	1 (0.0)	2 (0.0)	
 Americas	99796 (87.3)	16207 (78.7)	83589 (89.2)	
 South-East Asia	127 (0.1)	1 (0.0)	126 (0.1)	
 Europe	13384 (11.7)	4303 (20.9)	9081 (9.7)	
 Eastern Mediterranean	469 (0.4)	49 (0.2)	420 (0.5)	
 Western Pacific	514 (0.5)	42 (0.2)	472 (0.5)	
Reporting period	
 2015–2016	5 (0.0)	2 (0.0)	3 (0.0)	
 2017–2018	5422 (4.7)	1357 (6.6)	4065 (4.3)	
 2019–2020	45782 (40.1)	7323 (35.5)	38459 (41.1)	
 2021–2022	39591 (34.6)	8667 (42.1)	30924 (33.0)	
Notifier	
 Healthcare professional	70180 (61.4)	7176 (34.8)	63004 (67.3)	
 Non-healthcare professional	43322 (37.9)	13259 (64.4)	30063 (32.1)	
PCSK9 protein convertase subtilisin/kexin type

Association Between PCSK9 Inhibitors and Infection-Related AEs

Among 114,293 reports (258,099 drug–AE pairs) on PCSK9 inhibitors, 8464 reports (31,951 drug–AE pairs) were identified as infection-related AEs. Disproportionality analysis of the VigiBase dataset of safety reports associated with PCSK9 inhibitors highlighted 19 significant signals based on both the ROR and IC. The ROR of infectious AEs in the skin and respiratory, gastrointestinal, and renal systems was determined for alirocumab and evolocumab. The significant infection-related AEs were bronchitis (ROR 2.49, 95% CI 2.27–2.72), coronavirus infection (ROR 1.59, 95% CI 1.16–2.18), influenza (ROR 2.89, 95% CI 2.74–3.05), nasopharyngitis (ROR 4.47, 95% CI 4.30–4.64), sinusitis (ROR 2.91, 95% CI 2.70–3.14), diverticulitis (ROR 1.87, 95% CI 1.56–2.24), gastric infection (ROR 2.47, 95% CI 1.63–3.75), kidney infection (ROR 1.36, 95% CI 1.06–1.73), urinary tract infection (ROR 1.42, 95% CI 1.31–1.54), and dermatitis infected (ROR 2.94, 95% CI 1.23–7.04) (Fig. 2).Fig. 2 Results of signal detection for infection-related AEs of PCSK9 inhibitors. AE adverse event, CI confidence interval, IC information component, PCSK9 protein convertase subtilisin/kexin type 9, ROR reporting odds ratio

Co-Reported AEs with Infection-Related AEs

Concurrent reports of infection-related AEs were classified as SOCs. The top 10 overlapping datasets based on each patient report after PCSK9 inhibitor administration are shown in Fig. 3. Owing to the numerous combinations of infectious AEs and other concurrent classes, only the 38 most frequent overlaps were included. The most common overlapping SOCs were ‘musculoskeletal and connective tissue disorders’ (31.1%); ‘respiratory, thoracic, and mediastinal disorders’ (29.4%); and ‘gastrointestinal disorders’ (18.2%). Additionally, 4109 infection-related AEs were exclusively reported. The most reported SOC combination was ‘respiratory, thoracic, and mediastinal disorders’ (697 cases) with infection-related AEs. The second most reported overlapping combination was ‘musculoskeletal and connective tissue disorders’ (599 cases).Fig. 3 Co-reported AEs with infection-related AEs. ADR adverse drug reaction, AE adverse event. *Owing to the numerous combinations of infectious AEs and other concurrent classes, we present only the 38 most frequent overlaps

TTO Analysis

Among the significant infection-related AE signals, only a portion of ICSRs with respiratory tract infections were available for TTO analysis because of the small number of reported cases. Most initial respiratory tract infection AEs (70.0%) developed within 5 months of drug administration (Fig. 4). The median and interquartile range (IQR) TTO of initial infection-related AEs for respiratory tract diseases, including only significant signals in the main results, were 72 (23.5–202.5), 76 (13–140), and 104 (22–480.5) days for nasopharyngitis, rhinitis, and influenza, respectively. The median and IQR TTO for urinary tract infections were 34.5 (7.8–121.3) days.Fig. 4 TTO of infection-related AEs of PCSK9 inhibitors. AE adverse event, ICSR individual case safety report, IQR interquartile range, PCSK9 protein convertase subtilisin/kexin type 9, TTO time-to-onset. *Among the significant infection-related AE signals, only some ICSRs with respiratory tract infections were available using TTO with more than five reported cases

Sensitivity Analysis

Association Between Alirocumab and Infection-Related AEs

The number of infection-related reports associated with alirocumab was 1502. Disproportionality analysis was conducted on the VigiBase dataset of safety reports related to alirocumab, a PCSK9 inhibitor, focusing specifically on signals that were significantly prominent within the main result (Fig. 2). Utilizing both the ROR and IC, a total of 12 significant signals were identified within the existing set of 19 signals. Significant AEs that were excluded in comparison to the main results encompassed gastric infection, gastroenteritis viral, pharyngitis streptococcal, prostate infection, respiratory tract infection, and upper respiratory tract infection. Notably, no occurrences of ear, nose and throat infection were identified in the reported data. The significant infection-related AEs were bronchitis (ROR 3.28, 95% CI 2.76–3.90), coronavirus infection (ROR 2.63, 95% CI 1.53–4.53), influenza (ROR 3.07, 95% CI 2.73–3.44), nasopharyngitis (ROR 3.61, 95% CI 3.29–3.96), sinusitis (ROR 3.33, 95% CI 2.85–3.89), diverticulitis (ROR 2.43, 95% CI 1.72–3.43), kidney infection (ROR 1.74, 95% CI 1.08–2.80), urinary tract infection (ROR 1.96, 95% CI 1.68–2.28), and dermatitis infected (ROR 5.68, 95% CI 1.43–22.65). Furthermore, upon comparing the risk ratios for each AE associated with alirocumab in the ODYSSEY trial, a higher risk was observed compared with our analysis (Supplementary Table 2, see ESM).

Association Between Evolocumab and Infection-Related AEs

The number of infection-related reports associated with evolocumab was 5619. Disproportionality analysis was conducted on the VigiBase safety reports related to evolocumab focusing specifically on signals that were significant within the main result (Fig. 2). Utilizing both the ROR and IC, a total of 16 significant signals were identified within the existing set of 19 signals. Significant signals that were excluded in comparison to the main results included coronavirus infection, dermatitis infected, diverticulitis intestinal haemorrhagic, kidney infection, pharyngitis, and prostate infection. The significant infection-related AEs were bronchitis (ROR 2.27, 95% CI 2.04–2.53), influenza (ROR 2.83, 95% CI 2.67–3.01), nasopharyngitis (ROR 4.67, 95% CI 4.48–4.87), sinusitis (ROR 2.79, 95% CI 2.56–3.04), diverticulitis (ROR 1.72, 95% CI 1.39–2.12), gastric infection (ROR 2.69, 95% CI 1.72–4.21), and urinary tract infection (ROR 1.28, 95% CI 1.17–1.41). Moreover, our main results showed a higher risk of infection-related adverse events compared with alirocumab in the FOURIER trial (Supplementary Table 3, see ESM).

Sensitivity Analysis for the Risk of Infection-Related AEs with Statins

The results of the sensitivity analysis are consistent with the main results. Compared with statins, PCSK9 inhibitors exhibited a higher risk of ADRs belonging to the ‘infections and infestations’ SOC in ICSRs. The significant infection-related AEs were bronchitis (ROR 4.13, 95% CI 3.95–4.31), coronavirus infection (ROR 6.59, 95% CI 5.81–7.47), nasopharyngitis (ROR 7.81, 95% CI 7.70–7.92), diverticulitis (ROR 2.03. 95% CI 1.82–2.27), gastric infection (ROR 5.34, 95% CI 4.46–6.39), and urinary tract infection (ROR 2.46, 95% CI 2.35–2.58) (Supplementary Table 4, see ESM).

Discussion

We observed a broad range of infection safety profiles for alirocumab and evolocumab against gastrointestinal, renal, skin, and respiratory infections. This study found that musculoskeletal, respiratory, and gastrointestinal disorders were the most frequently reported SOCs associated with infection-related AEs. The most significant ADR signals occurred within approximately 5 months of treatment initiation. The main findings of this study demonstrated consistency across sensitivity analyses using different comparators. Given that most patients in these reports were older adults, our findings suggest that monitoring for infectious disorders should be performed during the early stages of PCSK9 inhibitor treatment in this population.

Randomized controlled trials (RCTs) assessing the clinical effects of PCSK9 inhibitors have shown a detrimental safety profile for infectious AEs [22–27]. Our findings are consistent with those of previous studies, implying that the risk of upper respiratory tract infection increases with PCSK9 inhibitors compared with other drugs. According to the labels of PCSK9 inhibitors, the most commonly reported AEs (>3% of patients) were upper respiratory tract infections, primarily nasopharyngitis, and influenza [37, 38]. In particular, the FOURIER and ODYSSEY studies, which investigated the infection-related incidence of PCSK9 inhibitors, indicated an elevated risk of nasopharyngitis in patients treated with PCSK9 inhibitors. The FOURIER-OLE study evaluated the effects of evolocumab in patients with established atherosclerotic cardiovascular disease and reported unexpected infection-related AEs. The incidence of influenza was slightly higher in patients treated with evolocumab during the integrated interim extension studies year 1 SoC (standard-of-care)-controlled period (45 cases/1489 patients, 3.0%) than in those who received the SoC (108 cases/2976 patients, 3.6%) [39]. Similarly, in the ODYSSEY FH II study, which evaluated long-term (78 weeks) efficacy and safety with hypercholesterolemia and high CVD risk, higher rates of influenza as infection-related AEs were more frequently reported in patients treated with alirocumab (24 cases/167 patients, 14.4%) than in those who received the placebo (7 cases/81 patients, 8.6%) [40]. Moreover, a study by Gürgöze et al. indicated that upper respiratory tract infections, especially nasopharyngitis, which is the most commonly reported AE in both the VigiLyze and Lareb databases, were reported in 16.2% of patients receiving PCSK9 inhibitors in the Erasmus Medical Centre hospital registry [41]. Hence, our findings were consistent with those of several studies and labels approved by both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), which reflect the commonly reported AEs based on RCT analyses. We observed additional outcomes, including higher rates of gastrointestinal, kidney, and skin infections, following the administration of PCSK9 inhibitors compared with other drugs. However, in the study conducted by Gürgöze et al., most reported infectious AEs resolved during the follow-up period [41]. We found that most respiratory tract infection-related AEs were reported within an average of 5 months. Additionally, Zhou et al. conducted a meta-analysis that included 20 RCTs, specifically examining severe infections (sepsis) and the association between sepsis and the use of PCSK9 inhibitors. This analysis demonstrated that PCSK9 inhibitor use was not linked to severe infection-related AEs, including sepsis, when compared with placebo (sepsis: RR 0.85, 95% CI 0.67–1.07; any severe infection: RR 0.96, 95% CI 0.89–1.03), and younger people are less likely to experience such events [30]. The majority of patients included in our study analysis who were using PCSK9i were elderly. Therefore, there is a critical need for additional long-term safety assessments of PCSK9i in the real-world setting, utilizing more comprehensive data. Therefore, our findings reveal that infection-related AEs associated with PCSK9 inhibitors may play an important role in the short-term prognosis of patients, especially older adults, and close monitoring is warranted to identify infectious conditions.

Current evidence suggests that AEs associated with infectious diseases are mechanically plausible. PCSK9 inhibitors are strictly linked to the metabolism of lipid and cholesterol via LDL-R regulation [42]. LDL-Rs are involved in cholesterol efflux capacity and macrophage functioning, which decreases cholesterol uptake [43–45]. Overall, decreased activity of PCSK9 inhibitors during infections, especially sepsis, may exhibit a harmful effect on the pathway of cholesterol metabolism and stimulate the immune system by possibly deteriorating lipid raft composition [28]. Specifically, the virus enters hepatic cells via LDL-R, which also plays a critical role in viral replication [46, 47]. Syed et al. observed that individuals infected with the virus had higher LDL-R levels in their hepatocytes compared with the control group [48]. Furthermore, the results of an in vitro study suggested that PCSK9 inhibitors may stimulate the upregulation of LDL-R with the participation of CD81 particles, enabling viral entry into the cells [29, 49]. Thus, the above evidence indicates that PCSK9 inhibitors may lead to increased susceptibility to bacterial and viral infection.

Our analysis identified nine SOCs associated with PCSK9 inhibitors. Our study exhibited high consistency in the rate of co-reported SOC incidence with previous studies of ADRs associated with PCSK9 inhibitors, including US FDA and EMA labels and clinical studies [23, 27, 37, 38, 50–53]. ‘Musculoskeletal and connective tissue disorders’ (31.1%), ‘respiratory, thoracic, and mediastinal disorders’ (29.4%), and ‘gastrointestinal disorders’ (8.2%) are some of the most common SOCs following PCSK9 inhibitor administration, according to both our study and the labels. This was consistent with the ranking of the most frequently reported combinations of SOCs and infection-related AEs (697, 599, and 292 cases, respectively). Given that coronavirus infection, identified in our study, can cause gastrointestinal symptoms such as diarrhea and nausea via pathophysiological mechanisms, the co-reported gastrointestinal ADRs may be additional AEs caused by infection-related AEs [54, 55].

To enhance the robustness of our findings, we conducted a sensitivity analysis by changing the comparator group from all other drugs to statins. Statins are commonly used as a first-line therapy to significantly reduce LDL-C levels, and concomitant administration of PCSK9 inhibitors is often considered in statin-intolerant cases [56]. We detected signals for infection-related AEs associated with PCSK9 inhibitors compared with statins, which was consistent with our primary findings that showed a higher risk of organ infections with PCSK9 inhibitors compared with other drugs. Furthermore, the sensitivity analysis was conducted to mitigate confounding by the indication that may arise from the analysis of PCSK9i versus all other drugs. The results of this analysis demonstrate a concerning association of infection-related AEs with both alirocumab and evolocumab. Therefore, consistent sensitivity analysis results with our main analysis indicate the robustness of our study findings.

Strengths and Limitations

To our knowledge, this is the first study to analyze the safety profile of PCSK9 inhibitors in terms of infectious AEs worldwide. This study has several strengths; it provides a comprehensive evaluation of ICSRs associated with PCSK9 inhibitors using the WHO’s VigiBase. Considering the lack of safety data in real-world settings, our study reflected the broad characteristics of the source data, including vulnerable patients (usually older adults) who were excluded from clinical trials. This study identified infection-related AEs across a comprehensive range of PCSK9 inhibitors. Evidence obtained from spontaneous reports will help improve the safety profiles of PCSK9 inhibitors.

Despite its strengths, this study has several limitations. This study was affected by the inherent limitations of spontaneous reporting databases, which cannot be used to deduce causal associations owing to underreporting and a potential lack of comparability. Therefore, reports are prone to selection bias owing to the reporter or reporting systems in different countries. Additionally, we could not determine whether the infections were solely attributable to the use of PCSK9 inhibitors. We also did not consider confounding factors such as health examinations and previous or current medical conditions. Further studies are required to confirm our findings and provide a more definitive assessment of the safety profile of PCSK9 inhibitors in terms of infectious AEs.

Conclusion

In addition to the labelled respiratory infections, we identified six infection-related symptoms affecting the gastrointestinal, urinary, and renal organs using the WHO’s VigiBase. Our findings align with those of a landmark RCTs of PCSK9 inhibitors, but we observed a broader spectrum of signals for infection-related AEs. Our study provides important insights into the safety profiles of PCSK9 inhibitors with respect to infection-related AEs and emphasizes the need for continued surveillance and monitoring. However, the clinical implications of our findings should be carefully considered because these signals were derived from spontaneous reporting systems. Further studies are required to establish a potential association between infection and PCSK9 inhibitor use.

Supplementary Information

Below is the link to the electronic supplementary material.Supplementary file1 (DOCX 33 KB)

We are grateful to the Ministry of Food and Drug Safety (MFDS) and Ministry of Science and ICT (MSIT) of South Korea for funding support.

Declarations

Funding

This work was supported by grants (21153MFDS607 and 22183MFDS433) from the Ministry of Food and Drug Safety of South Korea for the period 2021–2025 and grants (NRF-2022M3C1A3092022) from the Ministry of Science and ICT of South Korea. The funders played no role in the study design, data collection, data analysis, data interpretation, or writing of the manuscript. The corresponding author has full access to all data in the study and has the final responsibility for the decision to submit the manuscript for publication.

Ethical Approval

This study was approved by the Institutional Review Board of Sungkyunkwan University (IRB No. SKKU 2023-02-022), which waived the requirement for informed consent because this study used anonymized administrative data.

Conflict of Interest

The authors declare no conflicts of interest. Hoon Kim has received grants from the Ministry of Science and ICT. Ju-Young Shin has received grants from the Ministry of Food and Drug Safety, the National Research Foundation of Korea, and pharmaceutical companies, including Pfizer, Celltrion, and SK Bioscience. No other relationships or activities influenced the submission of this manuscript.

Consent to Participate

Formal consent is not necessary for this retrospective observational pharmacovigilance study.

Consent for Publication

Not applicable.

Data Availability

Data supporting the findings of this study are available from the Uppsala Monitoring Centre; however, restrictions apply to the availability of these data. The data were used under a licence for the current study and are not publicly available. Nevertheless, the data are available from the authors upon reasonable request and with permission from the Uppsala Monitoring Centre.

Code Availability

Not applicable.

Authors’ Contributions

Dahyun Park designed the study, collected the data, performed statistical analyses, interpreted the data, and wrote the manuscript. Sungho Bea designed the study, interpreted the data, and contributed to the writing of the manuscript. Ji-Hwan Bae and Hyesung Lee interpreted the data and contributed to the statistical analyses. Young June Choe critically interpreted the data and manuscript. Ju-Young Shin designed the study, supervised the statistical analyses and interpretation of the data, accepts full responsibility for the results of this study, has access to the data, and critically revised the manuscript. Hoon Kim, the guarantor of the study, accepts full responsibility for the results of this study, and controls the decision to publish. The corresponding authors attests that all listed authors meet the authorship criteria, and that no others meeting the criteria have been omitted. All authors read and approved the final version.

Dahyun Park and Sungho Bea have contributed equally to this work as co-first authors.

Ju-Young Shin and Hoon Kim have contributed equally to this work as co-corresponding authors.
==== Refs
References

1. Collaborators GBDHB Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 Lancet Gastroenterol Hepatol 2022 7 9 796 829 10.1016/S2468-1253(22)00124-8 35738290
Collaborators GBDHB. Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022;7(9):796–829.35738290 10.1016/S2468-1253(22)00124-8
2. Laslett LJ Alagona P Jr Clark BA 3rd Drozda JP Jr Saldivar F Wilson SR The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology J Am Coll Cardiol 2012 60 25 Suppl S1 49 10.1016/j.jacc.2012.11.002 23257320
Laslett LJ, Alagona P Jr, Clark BA 3rd, Drozda JP Jr, Saldivar F, Wilson SR, et al. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol. 2012;60(25 Suppl):S1-49.23257320 10.1016/j.jacc.2012.11.002
3. Roth GA Huffman MD Moran AE Feigin V Mensah GA Naghavi M Murray CJ Global and regional patterns in cardiovascular mortality from 1990 to 2013 Circulation 2015 132 17 1667 1678 10.1161/CIRCULATIONAHA.114.008720 26503749
Roth GA, Huffman MD, Moran AE, Feigin V, Mensah GA, Naghavi M, Murray CJ. Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation. 2015;132(17):1667–78.26503749 10.1161/CIRCULATIONAHA.114.008720
4. Dattani S, Samborska V, Ritchie H, Roser M. Cardiovascular Diseases Our World in Data. 2023. Available from: https://ourworldindata.org/cardiovascular-diseases.
5. Stone NJ Robinson JG Lichtenstein AH Bairey Merz CN Blum CB Eckel RH 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 2014 129 25 Suppl 2 S1 S45 24222016
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1–45.24222016
6. Virani SS Newby LK Arnold SV Bittner V Brewer LC Demeter SH 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: a report of the American Heart Association/American College of Cardiology joint committee on clinical practice guidelines Circulation 2023 148 9 e9 e119 10.1161/CIR.0000000000001168 37471501
Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: a report of the American Heart Association/American College of Cardiology joint committee on clinical practice guidelines. Circulation. 2023;148(9):e9–119.37471501 10.1161/CIR.0000000000001168
7. Mach F Baigent C Catapano AL Koskinas KC Casula M Badimon L 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Eur Heart J 2019 41 1 111 188 10.1093/eurheartj/ehz455
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2019;41(1):111–88.10.1093/eurheartj/ehz455
8. Pearson GJ Thanassoulis G Anderson TJ Barry AR Couture P Dayan N 2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults Can J Cardiol 2021 37 8 1129 1150 10.1016/j.cjca.2021.03.016 33781847
Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, et al. 2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021;37(8):1129–50.33781847 10.1016/j.cjca.2021.03.016
9. Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides. National Institue for Health and Care Excellence; 2022.
10. Ray KK Haq I Bilitou A Manu MC Burden A Aguiar C Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study Lancet Reg Health Eur 2023 29 100624 10.1016/j.lanepe.2023.100624 37090089
Ray KK, Haq I, Bilitou A, Manu MC, Burden A, Aguiar C, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health Eur. 2023;29: 100624.37090089 10.1016/j.lanepe.2023.100624
11. Mazhar F Hjemdahl P Clase CM Johnell K Jernberg T Sjölander A Carrero JJ Intensity of and adherence to lipid-lowering therapy as predictors of major adverse cardiovascular outcomes in patients with coronary heart disease J Am Heart Assoc 2022 11 14 e025813 10.1161/JAHA.122.025813 35861825
Mazhar F, Hjemdahl P, Clase CM, Johnell K, Jernberg T, Sjölander A, Carrero JJ. Intensity of and adherence to lipid-lowering therapy as predictors of major adverse cardiovascular outcomes in patients with coronary heart disease. J Am Heart Assoc. 2022;11(14): e025813.35861825 10.1161/JAHA.122.025813
12. Grundy SM Cleeman JI Merz CNB Brewer HB Clark LT Hunninghake DB Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines Arterioscler Thromb Vasc Biol 2004 24 8 e149 e161 15297292
Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Arterioscler Thromb Vasc Biol. 2004;24(8):e149–61.15297292
13. Officers TA, Group CftACR Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs DiureticThe Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 2002 288 23 2981 2997 10.1001/jama.288.23.2981 12479763
Officers TA, Group CftACR. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs DiureticThe Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–97.12479763 10.1001/jama.288.23.2981
14. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. The Lancet. 2002;360(9326):7-22.
15. Shepherd J Blauw GJ Murphy MB Bollen ELEM Buckley BM Cobbe SM Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial The Lancet 2002 360 9346 1623 1630 10.1016/S0140-6736(02)11600-X
Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. The Lancet. 2002;360(9346):1623–30.10.1016/S0140-6736(02)11600-X
16. Voutyritsa E Damaskos C Farmaki P Kyriakos G Diamantis E Quiles-Sanchez LV PCSK9 Antibody-based treatment strategies for patients with statin intolerance In Vivo 2021 35 1 61 68 10.21873/invivo.12232 33402450
Voutyritsa E, Damaskos C, Farmaki P, Kyriakos G, Diamantis E, Quiles-Sanchez LV, et al. PCSK9 Antibody-based treatment strategies for patients with statin intolerance. In Vivo. 2021;35(1):61–8.33402450 10.21873/invivo.12232
17. Nanchen D Carballo D Bilz S Rickli H Koskinas KC Mach F Effectiveness, adherence, and safety of evolocumab in a swiss multicenter prospective observational study Adv Ther 2022 39 1 504 517 10.1007/s12325-021-01962-w 34796465
Nanchen D, Carballo D, Bilz S, Rickli H, Koskinas KC, Mach F, et al. Effectiveness, adherence, and safety of evolocumab in a swiss multicenter prospective observational study. Adv Ther. 2022;39(1):504–17.34796465 10.1007/s12325-021-01962-w
18. Robinson JG Farnier M Krempf M Bergeron J Luc G Averna M Efficacy and safety of alirocumab in reducing lipids and cardiovascular events N Engl J Med 2015 372 16 1489 1499 10.1056/NEJMoa1501031 25773378
Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489–99.25773378 10.1056/NEJMoa1501031
19. Sabatine MS Giugliano RP Keech AC Honarpour N Wiviott SD Murphy SA Evolocumab and clinical outcomes in patients with cardiovascular disease N Engl J Med 2017 376 18 1713 1722 10.1056/NEJMoa1615664 28304224
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22.28304224 10.1056/NEJMoa1615664
20. Gaba P O’Donoghue ML Park J-G Wiviott SD Atar D Kuder JF Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE Circulation 2023 147 16 1192 1203 10.1161/CIRCULATIONAHA.122.063399 36779348
Gaba P, O’Donoghue ML, Park J-G, Wiviott SD, Atar D, Kuder JF, et al. Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE. Circulation. 2023;147(16):1192–203.36779348 10.1161/CIRCULATIONAHA.122.063399
21. O’Donoghue ML Giugliano RP Wiviott SD Atar D Keech A Kuder JF Long-term evolocumab in patients with established atherosclerotic cardiovascular disease Circulation 2022 146 15 1109 1119 10.1161/CIRCULATIONAHA.122.061620 36031810
O’Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation. 2022;146(15):1109–19.36031810 10.1161/CIRCULATIONAHA.122.061620
22. Giugliano RP Desai NR Kohli P Rogers WJ Somaratne R Huang F Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study Lancet 2012 380 9858 2007 2017 10.1016/S0140-6736(12)61770-X 23141813
Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012;380(9858):2007–17.23141813 10.1016/S0140-6736(12)61770-X
23. Koren MJ Scott R Kim JB Knusel B Liu T Lei L Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study Lancet 2012 380 9858 1995 2006 10.1016/S0140-6736(12)61771-1 23141812
Koren MJ, Scott R, Kim JB, Knusel B, Liu T, Lei L, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012;380(9858):1995–2006.23141812 10.1016/S0140-6736(12)61771-1
24. Cefalù AB Garbelotto R Mombelli G Pirro M Rubba P Arca M A subgroup analysis of the ODYSSEY APPRISE study: safety and efficacy of alirocumab in the Italian cohort Nutr Metab Cardiovasc Dis 2022 32 11 2638 2646 10.1016/j.numecd.2022.07.020 36064689
Cefalù AB, Garbelotto R, Mombelli G, Pirro M, Rubba P, Arca M, et al. A subgroup analysis of the ODYSSEY APPRISE study: safety and efficacy of alirocumab in the Italian cohort. Nutr Metab Cardiovasc Dis. 2022;32(11):2638–46.36064689 10.1016/j.numecd.2022.07.020
25. Raal FJ Honarpour N Blom DJ Hovingh GK Xu F Scott R Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial The Lancet 2015 385 9965 341 350 10.1016/S0140-6736(14)61374-X
Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. The Lancet. 2015;385(9965):341–50.10.1016/S0140-6736(14)61374-X
26. Farnier M Gaudet D Valcheva V Minini P Miller K Cariou B Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: pooled analysis of eight ODYSSEY Phase 3 clinical program trials Int J Cardiol 2016 223 750 757 10.1016/j.ijcard.2016.08.273 27573600
Farnier M, Gaudet D, Valcheva V, Minini P, Miller K, Cariou B. Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: pooled analysis of eight ODYSSEY Phase 3 clinical program trials. Int J Cardiol. 2016;223:750–7.27573600 10.1016/j.ijcard.2016.08.273
27. Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER)[Website]. 2022. https://clinicaltrials.gov/ct2/show/NCT01439880
28. Paciullo F Fallarino F Bianconi V Mannarino MR Sahebkar A Pirro M PCSK9 at the crossroad of cholesterol metabolism and immune function during infections J Cell Physiol 2017 232 9 2330 2338 10.1002/jcp.25767 28063230
Paciullo F, Fallarino F, Bianconi V, Mannarino MR, Sahebkar A, Pirro M. PCSK9 at the crossroad of cholesterol metabolism and immune function during infections. J Cell Physiol. 2017;232(9):2330–8.28063230 10.1002/jcp.25767
29. Labonte P Begley S Guevin C Asselin MC Nassoury N Mayer G PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression Hepatology 2009 50 1 17 24 10.1002/hep.22911 19489072
Labonte P, Begley S, Guevin C, Asselin MC, Nassoury N, Mayer G, et al. PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. Hepatology. 2009;50(1):17–24.19489072 10.1002/hep.22911
30. Zhou Z Zhang W Burgner D Tonkin A Zhu C Sun C The association between PCSK9 inhibitor use and sepsis: a systematic review and meta-analysis of 20 double-blind, randomized, placebo-controlled trials Am J Med 2023 136 6 558 67.e20 10.1016/j.amjmed.2023.02.025 36921646
Zhou Z, Zhang W, Burgner D, Tonkin A, Zhu C, Sun C, et al. The association between PCSK9 inhibitor use and sepsis: a systematic review and meta-analysis of 20 double-blind, randomized, placebo-controlled trials. Am J Med. 2023;136(6):558-67.e20.36921646 10.1016/j.amjmed.2023.02.025
31. Milazzo L Antinori S Effect of a monoclonal antibody to PCSK9 on LDL cholesterol New Engl J Med 2012 366 25 2425 10.1056/NEJMc1204929 22716983
Milazzo L, Antinori S. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. New Engl J Med. 2012;366(25):2425.22716983 10.1056/NEJMc1204929
32. Gürgöze MT Muller-Hansma AHG Schreuder MM Galema-Boers AMH Boersma E Roeters van Lennep JE Adverse events associated with PCSK9 inhibitors: a real-world experience Clin Pharmacol Ther 2019 105 2 496 504 10.1002/cpt.1193 30053327
Gürgöze MT, Muller-Hansma AHG, Schreuder MM, Galema-Boers AMH, Boersma E, Roeters van Lennep JE. Adverse events associated with PCSK9 inhibitors: a real-world experience. Clin Pharmacol Ther. 2019;105(2):496–504.30053327 10.1002/cpt.1193
33. Uppsala Monitoring Center. VigiBase. Available from: https://www.who-umc.org/vigibase/vigibase/.
34. Montastruc JL Sommet A Bagheri H Lapeyre-Mestre M Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database Brit J Clin Pharmaco. 2011 72 6 905 908 10.1111/j.1365-2125.2011.04037.x
Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Brit J Clin Pharmaco. 2011;72(6):905–8.10.1111/j.1365-2125.2011.04037.x
35. Puijenbroek EVBA Leufkens HGM Lindquist M Orre R Egberts A A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions Pharmacoepidemiol Drug Saf 2022 11 3 10 10.1002/pds.668
Puijenbroek EVBA, Leufkens HGM, Lindquist M, Orre R, Egberts A. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2022;11:3–10.10.1002/pds.668
36. Dolladille C Ederhy S Ezine E Choquet S Nguyen LS Alexandre J Chimeric antigen receptor T-cells safety: a pharmacovigilance and meta-analysis study Am J Hematol 2021 96 9 1101 1111 10.1002/ajh.26259 34057232
Dolladille C, Ederhy S, Ezine E, Choquet S, Nguyen LS, Alexandre J, et al. Chimeric antigen receptor T-cells safety: a pharmacovigilance and meta-analysis study. Am J Hematol. 2021;96(9):1101–11.34057232 10.1002/ajh.26259
37. FDA. Highlights of prescribing information - PRALUENT® (alirocumab) injection. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125559s002lbl.pdf.
38. FDA. Highlights of prescribing information - REPATHA® (evolocumab) injection. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125522s033lbl.pdf.
39. Toth PP Descamps O Genest J Sattar N Preiss D Dent R Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies Circulation 2017 135 19 1819 1831 10.1161/CIRCULATIONAHA.116.025233 28249876
Toth PP, Descamps O, Genest J, Sattar N, Preiss D, Dent R, et al. Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies. Circulation. 2017;135(19):1819–31.28249876 10.1161/CIRCULATIONAHA.116.025233
40. Kastelein JJ Ginsberg HN Langslet G Hovingh GK Ceska R Dufour R ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia Eur Heart J 2015 36 43 2996 3003 26330422
Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36(43):2996–3003.26330422
41. Gürgöze MT Muller-Hansma AHG Schreuder MM Galema-Boers AMH Boersma E van Lennep JER Adverse events associated with PCSK9 inhibitors: a real-world experience Clin Pharmacol Ther 2019 105 2 496 504 10.1002/cpt.1193 30053327
Gürgöze MT, Muller-Hansma AHG, Schreuder MM, Galema-Boers AMH, Boersma E, van Lennep JER. Adverse events associated with PCSK9 inhibitors: a real-world experience. Clin Pharmacol Ther. 2019;105(2):496–504.30053327 10.1002/cpt.1193
42. Thomas WM, editor Serum cholesterol: A Superior Prognostic Marker of Sepsis Mortality in the ICU Compared to Procalcitonin or C-reactive Protein 2015.
43. Annema W Tietge UJF Regulation of reverse cholesterol transport—a comprehensive appraisal of available animal studies Nutr Metab 2012 9 1 25 10.1186/1743-7075-9-25
Annema W, Tietge UJF. Regulation of reverse cholesterol transport—a comprehensive appraisal of available animal studies. Nutr Metab. 2012;9:1–25.10.1186/1743-7075-9-25
44. Shen L Peng HC Nees SN Zhao SP Xu DY Proprotein convertase subtilisin/kexin type 9 potentially influences cholesterol uptake in macrophages and reverse cholesterol transport FEBS Lett 2013 587 9 1271 1274 10.1016/j.febslet.2013.02.027 23499248
Shen L, Peng HC, Nees SN, Zhao SP, Xu DY. Proprotein convertase subtilisin/kexin type 9 potentially influences cholesterol uptake in macrophages and reverse cholesterol transport. FEBS Lett. 2013;587(9):1271–4.23499248 10.1016/j.febslet.2013.02.027
45. Seidah NG Benjannet S Wickham L Marcinkiewicz J Jasmin SB Stifani S The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation P Natl Acad Sci USA 2003 100 3 928 933 10.1073/pnas.0335507100
Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. P Natl Acad Sci USA. 2003;100(3):928–33.10.1073/pnas.0335507100
46. Burlone ME Budkowska A Hepatitis C virus cell entry: role of lipoproteins and cellular receptors J Gen Virol 2009 90 1055 1070 10.1099/vir.0.008300-0 19264629
Burlone ME, Budkowska A. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J Gen Virol. 2009;90:1055–70.19264629 10.1099/vir.0.008300-0
47. Albecka A Belouzard S de Beeck AO Descamps V Goueslain L Bertrand-Michel J Role of low-density lipoprotein receptor in the hepatitis C virus life cycle Hepatology 2012 55 4 998 1007 10.1002/hep.25501 22121002
Albecka A, Belouzard S, de Beeck AO, Descamps V, Goueslain L, Bertrand-Michel J, et al. Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology. 2012;55(4):998–1007.22121002 10.1002/hep.25501
48. Syed GH Tang HH Khan M Hassanein T Liu JW Siddiqui A Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation J Virol 2014 88 5 2519 2529 10.1128/JVI.02727-13 24352472
Syed GH, Tang HH, Khan M, Hassanein T, Liu JW, Siddiqui A. Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation. J Virol. 2014;88(5):2519–29.24352472 10.1128/JVI.02727-13
49. Le QT Blanchet M Seidah NG Labonte P Plasma membrane tetraspanin CD81 complexes with proprotein convertase Subtilisin/Kexin type 9 (PCSK9) and low density lipoprotein receptor (LDLR), and its levels are reduced by PCSK9 J Biol Chem 2015 290 38 23385 23400 10.1074/jbc.M115.642991 26195630
Le QT, Blanchet M, Seidah NG, Labonte P. Plasma membrane tetraspanin CD81 complexes with proprotein convertase Subtilisin/Kexin type 9 (PCSK9) and low density lipoprotein receptor (LDLR), and its levels are reduced by PCSK9. J Biol Chem. 2015;290(38):23385–400.26195630 10.1074/jbc.M115.642991
50. ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab[Website]. 2022. https://clinicaltrials.gov/ct2/show/NCT01663402 [
51. AlTurki A Marafi M Dawas A Dube MP Vieira L Sherman MH Meta-analysis of randomized controlled trials assessing the impact of proprotein convertase subtilisin/kexin type 9 antibodies on mortality and cardiovascular outcomes Am J Cardiol 2019 124 12 1869 1875 10.1016/j.amjcard.2019.09.011 31679643
AlTurki A, Marafi M, Dawas A, Dube MP, Vieira L, Sherman MH, et al. Meta-analysis of randomized controlled trials assessing the impact of proprotein convertase subtilisin/kexin type 9 antibodies on mortality and cardiovascular outcomes. Am J Cardiol. 2019;124(12):1869–75.31679643 10.1016/j.amjcard.2019.09.011
52. Choi J Khan AM Jarmin M Goldenberg N Glueck CJ Wang P Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study Lipids Health Dis 2017 10.1186/s12944-017-0493-7 28899385
Choi J, Khan AM, Jarmin M, Goldenberg N, Glueck CJ, Wang P. Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study. Lipids Health Dis. 2017. 10.1186/s12944-017-0493-7.28899385 10.1186/s12944-017-0493-7
53. Jones PH Bays HE Chaudhari U Pordy R Lorenzato C Miller K Robinson JG Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials Am J Cardiol 2016 118 12 1805 1811 10.1016/j.amjcard.2016.08.072 27729106
Jones PH, Bays HE, Chaudhari U, Pordy R, Lorenzato C, Miller K, Robinson JG. Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials. Am J Cardiol. 2016;118(12):1805–11.27729106 10.1016/j.amjcard.2016.08.072
54. Zhang J Garrett S Sun J Gastrointestinal symptoms, pathophysiology, and treatment in COVID-19 Genes Dis. 2021 8 4 385 400 10.1016/j.gendis.2020.08.013 33521210
Zhang J, Garrett S, Sun J. Gastrointestinal symptoms, pathophysiology, and treatment in COVID-19. Genes Dis. 2021;8(4):385–400.33521210 10.1016/j.gendis.2020.08.013
55. Zhang T Liu D Tian D Xia L The roles of nausea and vomiting in COVID-19: did we miss something? J Microbiol Immunol Infect 2021 54 4 541 546 10.1016/j.jmii.2020.10.005 34435559
Zhang T, Liu D, Tian D, Xia L. The roles of nausea and vomiting in COVID-19: did we miss something? J Microbiol Immunol Infect. 2021;54(4):541–6.34435559 10.1016/j.jmii.2020.10.005
56. Gallego-Colon E Daum A Yosefy C Statins and PCSK9 inhibitors: a new lipid-lowering therapy Eur J Pharmacol 2020 878 173114 10.1016/j.ejphar.2020.173114 32302598
Gallego-Colon E, Daum A, Yosefy C. Statins and PCSK9 inhibitors: a new lipid-lowering therapy. Eur J Pharmacol. 2020;878: 173114.32302598 10.1016/j.ejphar.2020.173114
